Journal of the Advanced Practitioner in Oncology
Overview
Journal of the Advanced Practitioner in Oncology is a scientific journal, published since 2010 in English. The journal's country of origin is United States.
Details
Details
Abbr.
J Adv Pract Oncol
Start
2010
End
Continuing
Frequency
Seven issues a year, 2023-
p-ISSN
2150-0878
e-ISSN
2150-0886
Country
United States
Language
English
Recent Articles
1.
Brooks D, Bourassa D, Elwell J, Baker J
J Adv Pract Oncol
. 2025 Feb;
:1-8.
PMID: 39990045
Purpose: The purpose of this quality improvement project was to evaluate the use of a posttransplant screening care guidelines template performed by advanced practice providers (APPs) that included standards of...
2.
Tetzlaff E, Ruth K, Hylton H, Hasse Z
J Adv Pract Oncol
. 2025 Feb;
:1-10.
PMID: 39990044
Introduction: The COVID-19 pandemic led to rapid changes in the delivery of oncology care. Studies examining the impact of the pandemic on the oncology workforce are largely limited to oncologists...
3.
Osburn J, Martinez A, Dains J
J Adv Pract Oncol
. 2025 Feb;
:1-10.
PMID: 39990043
Hematopoietic stem cell transplantation (HSCT) is an intensive treatment requiring the support of a caregiver. This role is a highly demanding responsibility, and caregivers often face distress. In a world...
4.
Ow K
J Adv Pract Oncol
. 2025 Feb;
:1-15.
PMID: 39990042
Chimeric antigen receptor (CAR) T-cell therapy has ushered in a transformative era in the management of relapsed/refractory hematologic malignancies. The extensive phase II trials targeting relapsed/refractory non-Hodgkin lymphoma, including diverse...
5.
Johnson C, Martinez A, Dains J
J Adv Pract Oncol
. 2025 Feb;
:1-11.
PMID: 39990041
Colorectal cancer (CRC) is a significant cause of morbidity and mortality, with incidence on the rise, particularly in younger adults. Surgery is a key treatment modality and often results in...
6.
Geppner A
J Adv Pract Oncol
. 2025 Feb;
16(1):30-36.
PMID: 39959690
Aplastic anemia (AA) is a bone marrow failure disorder resulting in peripheral pancytopenia and marrow hypoplasia. An alternative diagnosis of hypoplastic myelodysplastic syndrome (MDS) can overlap this diagnosis but is...
7.
Doubleday E, Alker P
J Adv Pract Oncol
. 2025 Feb;
16(1):23-29.
PMID: 39959689
Individuals who are at a high risk for breast cancer are a unique population. These women and men may be eligible for additional screenings for breast cancer and require education...
8.
Clermont L, Lewis M, Jung S, Wheatley T, Robbins W
J Adv Pract Oncol
. 2025 Feb;
16(1):15-22.
PMID: 39959688
Background: Nurse practitioners (NPs) entering the malignant hematology specialty often lack hematology-specific knowledge needed for practice; many have reported they want and need more hematology education. Deficiencies in hematology education...
9.
10.
Zacholski E, Rugh S, Marshall J, Nadpara P, Moore D
J Adv Pract Oncol
. 2025 Jan;
15(7):437-443.
PMID: 39830224
Introduction: Despite standard prevention strategies, obinutuzumab carries a significant risk of infusion-related reactions (IRRs) for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Reported rates of IRRs vary in phase...